SEARCH
Toggle navigation
HOME
COMPANY
TECHNOLOGY
IMMUNOBODY
MODITOPE
AVIDIMAB
SCIENTIFIC PAPERS & POSTERS
PRODUCTS
PRODUCT PIPELINE
SCIB1
SCIB2
Modi-1
Modi-2
INVESTORS
COMPANY PROFILE
ADVISORS
CORPORATE GOVERNANCE
DOCUMENTS & PRESENTATIONS
SHARE INFO
FINANCIAL INFO
REGULATORY NEWS
REGULATORY NEWS ARCHIVE
NEWS
LATEST NEWS
INTERVIEWS
MEDIA COVERAGE
REGULATORY NEWS
WEBCASTS
YEAR - 2020
YEAR - 2019
YEAR - 2018
YEAR - 2017
YEAR - 2016
YEAR - 2015
CONTACT US
SEARCH
INVESTORS
HOME
COMPANY
TECHNOLOGY
IMMUNOBODY
MODITOPE
AVIDIMAB
SCIENTIFIC PAPERS & POSTERS
PRODUCTS
PRODUCT PIPELINE
SCIB1
SCIB2
Modi-1
Modi-2
INVESTORS
COMPANY PROFILE
ADVISORS
CORPORATE GOVERNANCE
DOCUMENTS & PRESENTATIONS
SHARE INFO
FINANCIAL INFO
REGULATORY NEWS
REGULATORY NEWS ARCHIVE
NEWS
LATEST NEWS
INTERVIEWS
MEDIA COVERAGE
REGULATORY NEWS
WEBCASTS
YEAR - 2020
YEAR - 2019
YEAR - 2018
YEAR - 2017
YEAR - 2016
YEAR - 2015
CONTACT US
Investor Information
Scancell Holdings PLC is an AIM listed company
Advisors
Share Information
Corporate Governance
Financial Information
Documents & Presentations
Regulatory News
Press Releases
SCIB1 IND application approved
To download
click here
Scancell Interim Results
To download
click here
Third agreement signed for antibody platform
To download
click here
View all posts
»